Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and Tagitanlimab (KL-A167) in the treatment of AVPC (aggressive variant prostate cancer) and NEPC (neuroendocrine prostate cancer).

Trial Details

NCT ID
NCT07179783
Phase
PHASE2
Sponsor
Tianjin Medical University Second Hospital
Status
RECRUITING
Cancer Type
Neuroendocrine Prostate Cancer
Interventions
  • Sacituzumab Tirumotecan
  • Tagitanlimab
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Age at the time of signing the informed consent form is ≥ 18 years old;
  • AVPC or NEPC diagnosed based on recent histological and/or clinical criteria;
  • Having received one or two second-generation anti androgen therapies in the past, previous use of docetaxel for castration resistant prostate cance…
  • The progression of prostate cancer in the subjects within 6 months prior to screening shall be determined by the researcher through one of the foll…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Neuroendocrine Prostate Cancer Trials on Trialify →